China approves new generation of domestic lung cancer innovative drug

According to ThePaper, a new generation of domestic lung cancer innovative drug Ameitini (阿美替尼) was officially put into the market.
The full name of the medicinal chemistry is Almonertinib Mesilate Tablets and the trade name is Ameitini.

According to ThePaper, a new generation of domestic lung cancer innovative drug Ameitini (阿美替尼) was officially obtained official approval.

The full name of the medicinal chemistry is Almonertinib Mesilate Tablets and the trade name is Ameitini.

Ameitini is the second in the world independently and also the first domestic third-generation EGFR-TKI innovative drug, developed by Hansoh Pharma.

It is used to treat locally advanced or metastatic non-small cell lung cancer with positive EGFR T790M mutation.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/11/china-approves-new-generation-of-domestic-lung-cancer-innovative-drug/.

Leave a Reply

Please Login to Comment